A study to evaluate the efficacy, safety and tolerability of co-administered lopinavir/ritonavir (LPVr) and nevirapine (NVP) in HIV-infected adults

Methods In this prospective, 48-week, two-centre study, 40 patients were recruited to receive lopinavir/ritonavir (LPV/r) soft gel capsules (SGC) (533/133 mg BID) plus nevirapine (NVP) (200 mg BID). Once HIV-RNA was <50 copies/ml, patients were allowed to switch to the new LPV/r tablet formulation (400/100 mg BID); this was not considered a switch in the analyses. Fasting lipids, CD4 count, and HIV-1 RNA were performed on days 1, 4 and 7 and weeks 2, 4, 12, 24, 36 and 48. Analyses were intention-to-treat (ITT; switch & missing = failure) and on treatment.